Skip to main content
SpringerLink
Log in

Schwerpunkt Hodgkin-Lymphom

Evidenzbasierte Erstlinientherapie des Hodgkin-Lymphoms

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

Die aktuelle Erstlinientherapie des Hodgkin-Lymphoms basiert im Wesentlichen auf Polychemotherapien plus Radiatio. Vorgehen und Intensität der Therapie werden dabei an der risikoadaptierten Stadieneinteilung gemäß der German Hodgkin Study Group ausgerichtet. Lesen Sie im Folgenden, was das in der Praxis bedeutet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

T1
1
2
3

Literatur

  1. Eichenauer DA et al. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant HLa: A Report From the German Hodgkin Study Group. J Clin Oncol. 2015;33(26):2857–62

    Article  CAS  Google Scholar 

  2. Specht L et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin’s Disease Collaborative Group. J Clin Oncol. 1998;16(3):830–43

    Article  CAS  Google Scholar 

  3. Engert A et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–52

    Article  CAS  Google Scholar 

  4. Behringer K et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385(9976):1418–27

    Article  CAS  Google Scholar 

  5. Andre MPE et al. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II HLa: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017;35(16):1786–94

    Article  CAS  Google Scholar 

  6. Fuchs M et al. PET-Guided Treatment of Early-Stage Favorable HLa: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group. Blood. 2018;132(Suppl 1):925

    Google Scholar 

  7. Specht L et al. Modern radiation therapy for HLa: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–62

    Article  Google Scholar 

  8. Sasse S et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage HLa: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol. 2017;35(18):1999–2007

    Article  CAS  Google Scholar 

  9. Eich HT et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–206

    Article  Google Scholar 

  10. von Tresckow B et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907–13.

    Article  CAS  Google Scholar 

  11. Radford J et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–607

    Article  CAS  Google Scholar 

  12. Hasenclever D et al. Modelling of chemotherapy: the effective dose approach. Ann Hematol. 2001;80 Suppl 3:B89–94

    CAS  PubMed  Google Scholar 

  13. Engert A et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–54

    Article  Google Scholar 

  14. Engert A et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–9

    Article  CAS  Google Scholar 

  15. Borchmann et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2018;390(10114):2790–802

    Article  Google Scholar 

  16. Viviani S et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–12

    Article  CAS  Google Scholar 

  17. Connors JM et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018;378(4):331–44

    Article  CAS  Google Scholar 

  18. Engert A et al. Hodgkin’s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin’s Study Group. J Clin Oncol. 2005;23(22):5052–60

    Article  Google Scholar 

  19. Boll B et al. Bleomycin in older early-stage favorable HLa patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127(18):2189–92

    Article  Google Scholar 

  20. Boll B et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage HLa. Blood. 2011;118(24):6292–8

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf, Universität zu Köln, Klinik I für Innere Medizin, Köln, Deutschland

    Jesko Momotow & Andreas Engert

  2. German Hodgkin Study Group (GHSG), Köln, Deutschland

    Jesko Momotow & Andreas Engert

  3. Studienzentrum der Klinik I für Innere Medizin, Universitätsklinikum Köln, German Hodgkin Study Group (GHSG), Kerpener Straße 62, 50937, Köln, Deutschland

    Jesko Momotow

Authors
  1. Jesko Momotow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Engert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jesko Momotow.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Momotow, J., Engert, A. Evidenzbasierte Erstlinientherapie des Hodgkin-Lymphoms. Info Onkol. 22, 10–15 (2019). https://doi.org/10.1007/s15004-019-6699-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6699-2

Search

Navigation